Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colitis, Ulcerative: full-pipeline trial registry
10 of 29 indexed Colitis, Ulcerative trials are currently recruiting.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 10 currently recruiting · #552 of 28,707 conditions by registered trial count
Colitis, Ulcerative: 29 US clinical trials tracked, 10 recruiting.
Colitis, Ulcerative is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 10 of these trials.
Enrollment posture brief
Registry condition colitis-ulcerative
OPEN 10 | RECR 34% | LATE 12 | EARLY 14 | RANK #552 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Overweight and Obesity (34% recruiting · 116 trials)
Colitis, Ulcerative lists 10 open slots (34% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Colitis, Ulcerative on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Colitis, Ulcerative is recruiting below its size-band peers.
10 of 29 indexed trials (34.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Colitis, Ulcerative research.
Janssen Research & Development accounts for 10 of 29 trials (34.5%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Colitis, Ulcerative enrolment sits around 247 participants.
Median target enrolment is 247 among the 29 trials that report a genuine target (sentinel values excluded). 7 of those (24.1%) plan for fewer than 100 participants.
-
Colitis, Ulcerative research is mostly interventional.
26 interventional and 3 observational studies make up this index (89.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Merck Sharp & Dohme
NCT06651281
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Janssen Scientific Affairs
NCT04372108
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT07196748
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Spyre Therapeutics
NCT07012395
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Pfizer
NCT06398626
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Sanofi
NCT06867094
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development
NCT06663332
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Bristol-Myers Squibb
NCT05076175
Therapeutic Endpoint in Pediatric IBD Conditions
Children's National Research Institute
NCT06065228
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
University of California, San Diego
NCT04721873
Determination of the Optimal Treatment Target in Ulcerative Colitis
Alimentiv
NCT04259138
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT05242484
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT05528510
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
NCT05611671
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Teva Branded Pharmaceutical Products R&D
NCT05668013
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Oppilan Pharma
NCT05156125
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Sanofi
NCT05588843
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Janssen Research & Development
NCT05092269
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT06260163
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT03596645
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
Sanofi
NCT05731128
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT00487539
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT02407236
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
Takeda
NCT02497469
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Teva Branded Pharmaceutical Products R&D
NCT05499130
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Takeda
NCT03029143
Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
Telavant
NCT02840721
A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis
Janssen Research & Development
NCT01900574
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
Takeda
NCT02559713
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 13 |
| Phase 3 | 9 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Colitis, Ulcerative records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Colitis, Ulcerative trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Colitis, Ulcerative page
29 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Colitis, Ulcerative trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Colitis, Ulcerative trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colitis, Ulcerative condition card totals 29 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.